A brand-new, evidence-based, self-evaluation toolkit to support pharma companies become more patient-centric.
- PatientView's original Being Patient-Centric toolkit was launched in November 2017. In November and December 2018, PatientView published two supplements to the toolkit, looking at the specific challenges of Being Patient-Centric in Drug Research and Development: from a global perspective, and from a US perspective.
- Pricing information can be found at the bottom of this webpage.
The groundbreaking November 2017 Being Patient-Centric toolkit analysed 2016-2017 feedback from:
"The new November 2017 self-evaluation toolkit explores the most practical and comprehensive approach I have ever observed across the existing assessment frameworks for patient-centric programmes and initiatives.
Every aspect must be taken into consideration when analysing what a company does to address unmet patient needs, hopes and expectations delivering real value. The industry, patients and community still have a challenge of inconsistency and absence of unified methodology clear for all and easily implementable by several stakeholders.
I believe that the tool will help to identify any gaps/opportunities within engagement with patients as well as caregivers, advocates, activists and members of patient organisations; develop patient-centric strategy and address cross-stakeholder inconsistency."
Dr Oleksandr Gorbenko, ViiV Healthcare
At the end of 2018, PatientView launched two new supplements to its Being Patient-Centric toolkit, focusing on patient/patient-group involvement in R&D from ...
(1) a global perspective, and (2) a US perspective.
Both 2018 supplements are intended to be used in conjunction with PatientView's evidence-based Being Patient-Centric toolkit (published November 2017), which identified nine key attributes of patient centricity.
Why focus on drug R&D?
Pharma's success at one of the nine attributes of patient-centricity, engaging patients in R&D, has consistently been rated as unimpressive by patient groups. PatientView's 2017 Corporate Reputation of Pharma survey (results published April 2018) found that 59% of the 1,300 respondent patient groups thought pharma just "Fair" to "Poor" at engaging patients/patient groups in product research; and 60% thought the same about pharma's record at engaging patients/patient groups in product development. Worldwide, only 13% of patient groups responding to PatientView’s 2017 Corporate Reputation of Pharma survey said that they worked with pharma companies on clinical research, and only 12% said that they worked with pharma on clinical trials.
Patient-centric drug R&D: an area in need of improvement
Pharma's poor performance at engaging patients/patient groups in R&D prompted PatientView to focus further surveys, research, and analysis on the subject during 2018. This activity has led to these two, new, late-2018, in-depth supplements to the original November 2017 Being Patient-Centric toolkit. Both of the 2018 supplements provide companies with evidence-based strategy on the topic of patient-centric drug R&D.
The global perspective: published December 2018 (BPC/#2).
This December 2018 supplement to the November 2017 Being Patient-Centric toolkit takes a deep dive into comments received from 2,000 patient groups worldwide, 2017-2018, on what precisely is needed for companies to be more patient-centric in R&D.
The December 2018 global supplement provides:
The US perspective: published November 2018 (BPC/#1).
Since 2016, the Food and Drug Administration (FDA) has been actively promoting programmes which put patients at the heart of drug research and development (R&D), through its 'Patient Focused Drug Development' (PFDD) initiative. Because of the importance of the FDA’s PFDD initiative, and the heightened activity of US patient groups in drug R&D, PatientView decided to conduct a survey of patient groups in the US on the subject. The survey ran August-October 2018, and this November 2018 supplement (and its Appendix) contains the survey’s results.
The Being Patient-Centric package consists of three items: (1.) the November 2017 Being Patient-Centric toolkit; (2.) the November 2018 US supplement, entitled US Patient-Group Perspectives on Patient-Centric R&D; and (3.) the December 2018 global supplement, The Opinions of Patient Groups Worldwide on Patient Engagement in Drug R&D.